AHK-Cu vs Dutasteride
A side-by-side research comparison of AHK-Cu and Dutasteride across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AHK-Cu | Dutasteride |
|---|---|---|
| Full name | AHK-Cu (Alanine-Histidine-Lysine Copper Peptide) | Dutasteride (Avodart) |
| Category | Hair Growth | Hair Growth |
| Status | Cosmetic research peptide | FDA Approved (BPH) / Off-label hair loss |
| Mechanism | Delivers copper to tissue and signals angiogenesis and growth-factor activity (notably VEGF) around hair follicles, promoting follicle vascularization, prolonging the anagen (growth) phase, and supporting collagen production. | Inhibits both type I and type II 5-alpha reductase isoenzymes, reducing serum DHT by ~90% and scalp DHT by ~50%. Prevents miniaturization of androgen-sensitive hair follicles in the vertex and frontal scalp. |
| Molecular weight | ~403 Da (with copper) | 528.53 Da |
| Half-life | Topical (local action) | ~5 weeks (extremely long) |
| Bioavailability | Topical (serum/solution); local delivery | ~60% oral |
| Typical dose | ~0.5-2 mg/mL topical serum | 0.5 mg |
| Frequency | 1-2x daily on scalp | Daily |
| Route | Topical | Oral capsule |
AHK-Cu reported benefits
- Hair follicle support and growth signaling
- Follicle vascularization (VEGF)
- Prolongs anagen growth phase
- Collagen and skin support
- Antioxidant copper delivery
Dutasteride reported benefits
- Superior DHT suppression vs finasteride
- Hair regrowth and thickening
- Reduced hair miniaturization
- Prostate volume reduction
- Effective for diffuse thinning
Related comparisons
Research and educational reference only. Not medical advice.